U.S. regulators have granted fast track status to the Experimental Drug Development Centre’s (EDDC’s) candidate therapy for pancreatic ductal adenocarcinoma (PDAC), an aggressive form…
News
The first participant has been dosed in a Phase 1/2 trial investigating TNG456, a PRMT5 inhibitor to treat people with advanced solid tumors with MTAP…
When added to standard care, Imunon’s immunotherapy candidate IMNN-001 extended the average survival for people with newly diagnosed advanced ovarian cancer by more than…
A U.S. Food and Drug Administration (FDA) committee has voted in favor of Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat high-risk smoldering multiple myeloma…
Geneseeq Technology is developing a blood test that uses cell-free DNA (cfDNA) and artificial intelligence (AI) to detect early-stage pancreatic ductal adenocarcinoma — the…
BCB-276, an experimental cell therapy that Brainchild Bio is developing for diffuse intrinsic pontine glioma (DIPG), has been named a regenerative medicine advanced…
Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among people with platinum-resistant ovarian cancer…
Nearly all the people with relapsed or refractory multiple myeloma (RRMM) who took part in a Phase 2 clinical trial responded to the cell…
ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients…
Adding the experimental therapy elraglusib to standard chemotherapy led to statistically significant improvements in survival for people with metastatic pancreatic ductal adenocarcinoma (PDAC), a form…
